Study of H. Pylori Infection Recurrence and Influential Factors in Adults Aged 18 to 75 in Sohag Government
Led by Sohag University · Updated on 2025-07-01
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
The trial investigates the recurrence of H. Pylori infection in patients who previously received medical treatment. It aims to determine how often the infection returns, identify factors that influence this recurrence, and evaluate the effectiveness of different treatment regimens in reducing the chance of the infection coming back.
Participants are followed up after their initial successful treatment for H. Pylori infection to monitor recurrence and assess various influential factors. The study focuses on patients aged 18 to 75 years who have had confirmed H. Pylori infection and received medical treatment. This follow-up is designed to gather information over time about the infections return.
During the study, participants will be monitored for signs of H. Pylori recurrence four weeks after treatment completion. Researchers will evaluate symptoms related to the infection and perform necessary tests to check for recurrence. The main outcome measured is the rate of H. Pylori infection returning after therapy. Safety and health status will be observed throughout the follow-up period, with participation lasting according to the study timeline ending in November 2025.
CONDITIONS
Brief Title
Recurrence of H Pylori : Incidence and Influential Factors.
Research Team
T
Thomas W Thabet, Resident
U
Usama M Abdelaal, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Confirmed H. pylori infection by endoscopy, biopsy, or non-invasive tests such as urea breath test or stool antigen test
Presence of symptoms like dyspepsia, peptic ulcer disease, or other related symptoms
Normal liver and kidney function and no significant abnormalities in blood counts
You will not qualify if you...
Use of proton pump inhibitors, H2 blockers, bismuth, antibiotics, or other medications that affect test results within the past 4 weeks
Severe gastrointestinal disorders including gastric cancer, inflammatory bowel disease, or recent bleeding ulcers
Active or recent malignancies
Unstable or severe comorbid conditions such as heart failure or liver cirrhosis
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Outpatient Treatment
Duration - 4 weeks after successful medical treatment
Participants who had H. Pylori infection and received medical treatment are followed up to observe recurrence and influential factors.
Follow-up visits during this period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Similar Trials
A Pilot Study Comparing 14-Day Vonoprazan-Based Dual, Triple, Bismuth Quadruple, Reverse Hybrid, and Lansoprazole-Based Therapies for First-Line Treatment of Helicobacter Pylori Infection
Study of Vonoprazan Dual and Triple Therapy Compared to PPI Triple Therapy to Treat Helicobacter Pylori Infection in Adults
European Multicenter Registry Tracking Diagnosis and Treatment of Helicobacter pylori Infection in Adults
Study of Argon Plasma Activated Liquid to Treat Helicobacter pylori Infection During Endoscopy
Comparing Direct Stomach Treatment vs. Pre-Prepared Solution
Study of H. Pylori Infection Recurrence and Influential Factors in Adults Aged 18 to 75 in Sohag Government
Finding the Best Screening Method to Prevent Gastric Cancer by Detecting H. pylori Infection in Adults
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse: comparison of 1 week and 2 week regimens and recrudescence rates over 12 months.